LP
RARE icon

Longaeva Partners’s Ultragenyx Pharmaceutical RARE Stock Holding History

Longaeva Partners’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.38M Sell
41,347
-186,760
-82% -$4.64M 0.03% 279
2026
Q1 		$4.78M Buy
+228,107
New +$5.14M 0.18% 113

Other funds holding RARE

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return

Longaeva Partners's RARE Position: Q2 2026 in Review

Longaeva Partners reduced its Ultragenyx Pharmaceutical (RARE) stake by 82% in Q2 2026, selling an estimated $4.64M and leaving 41,347 shares worth $1.38M. The position accounts for 0.03% of the portfolio, ranked #279.

Longaeva Partners first reported a position in RARE in Q1 2026 and has held it in 2 quarters since. The position peaked at $4.78M in Q1 2026. 311 funds tracked by Wall St. Rank hold RARE as of Q2 2026.

  • Longaeva Partners held 41,347 shares of Ultragenyx Pharmaceutical worth $1.38M as of Q2 2026.
  • Longaeva Partners sold 186,760 Ultragenyx Pharmaceutical shares in Q2 2026, an estimated $4.64M.
  • Ultragenyx Pharmaceutical made up 0.03% of Longaeva Partners's portfolio in Q2 2026, its #279 holding.
  • Longaeva Partners first reported a position in Ultragenyx Pharmaceutical in Q1 2026 and has held it in 2 quarters since.
  • Longaeva Partners's Ultragenyx Pharmaceutical position peaked at $4.78M in Q1 2026.
  • 311 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q2 2026.

Based on Longaeva Partners's 13F filing for Q2 2026, filed 14 Aug 2026.